Back

Factors associated with NT-proBNP reduction in acute heart failure: a secondary analysis of the PREMIER trial

10 May 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Enhanced aspects of clinical care Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Yosuke Nabeshima

Saga University Hospital, Saga (Japan)

6 More presentations in this session

Presentation thumbnail
Long term follow-up of autosomal recessive atrial dilated cardiomyopathy associated with mutation of natriuretic peptide precursor A
Doctor M. Iseppi (Trento, IT)
Abstract Slides Video
Presentation thumbnail
Operational characteristics of a clinical algorithm to optimize the detection of undiagnosed heart failure in primary care: insights from a prospective, multicenter study
Professor S. Stewart (Fremantle, AU)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence-enabled electrocardiography for identifying heart failure in patients with dyspnea in the emergency department
Associate Professor J. Park (Seongnam, KR)
Abstract Slides Video
Presentation thumbnail
AI-enabled ECG imaging for the detection of cardiac amyloidosis across amyloidosis subtypes
Miss A. Achten (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Circulating dipeptidyl peptidase 3 levels in acute heart failure: insights from the PUSH-AHF trial
Mr S. Legtenberg (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Enhanced aspects of clinical care

The Event

Event poster

Heart Failure 2026

10 May 2026 15:30 CET
You may be interested in
thumbnail
Congress Presentation
Early in-hospital initiation of angiotensin-neprilysin inhibition in Japanese patients with acute heart failure: the investigator-initiated multicenter randomized PREMIER study
thumbnail
Congress Presentation
Clinical Implications of NT-proBNP trajectory following Sacubitril/Valsartan initiation
thumbnail
Congress Presentation
Impact of af on sacubitril/valsartan dosing, persistance of treatment and associated outcomes in heart failure patients with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources